USPTO serial 87777607
ENGENSIS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 12, 2019
- Examiner
- FIRST, VIVIAN M
- Law office
- Historical data usage
What this means
Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use. Continue use in commerce and plan for the 10-year Section 8 and 9 renewal.
Need help with ENGENSIS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
SEOUL, KR
Gwanak-gu, Seoul, KR
Gwanak-gu, Seoul, KR
Gwanak-gu, Seoul, KR
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Daniel P. Mullarkey
Daniel P. Mullarkey POLSINELLI PC1401 EYE STREET, NW, SUITE 800WASHINGTON, DC 20005United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Chemical reagents for use in veterinary genetic testing; reagents for use in medical genetic testing; diagnostic preparations for medical purposes for detecting mutation in prion genes; preparations for medical purposes for detecting mutation in prion genes; chemical preparations for pharmaceutical purposes, namely, for painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; drugs for medical purposes, namely, prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; pharmaceutical preparations for the treatment of painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; medicines for human purposes, namely, pharmaceutical preparations for the treatment of painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; pharmaceutical preparations for diagnosis of painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; ethical medicinal preparations, namely, pharmaceutical preparations for the treatment of painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; pharmaceutical preparations for the treatment of immune system related diseases and disorders; chemical preparations for use in medical DNA analysis; genetic treatment pharmaceutical preparations | ACTIVE | — |
| 042 | Pharmaceutical research and development; pharmaceutical research services; consultancy relating to pharmaceutical research and development; research and development of vaccines and medicines; scientific research in the fields of biomedicine; research and testing services in the fields of bacteriology and virology; drug discovery services; research and development in the pharmaceutical and biotechnology fields; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; consultancy in analysis of biology sequence processing for medical research purposes; consultancy in analysis of genomics for medical research purposes; scientific research in the fields of medicine, health and pharmacology; analysis of human serum for medical research; analysis of human tissues for medical research; blood analysis services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by HELIXMITH CO., LTD
- Other trademarks owned by ViroMed Co., Ltd.
- Other trademarks owned by ViroMed Co., Ltd.
- Other trademarks owned by ViroMed Co., Ltd.
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named ENGENSIS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 9, 2025 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Jun 9, 2025 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Jun 9, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Feb 13, 2025 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Mar 12, 2024 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Jun 19, 2019 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| May 10, 2019 | CORV | REVIEW OF CORRESPONDENCE COMPLETE - CERTIFICATE OF REG MAILED | — |
| Mar 12, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 5, 2019 | DP1B | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | — |
| Feb 5, 2019 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Dec 21, 2018 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Dec 21, 2018 | D1BR | TEAS DELETE 1(B) BASIS RECEIVED | — |
| Nov 27, 2018 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 2, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 2, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 12, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 24, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 23, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 23, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 23, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 14, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 14, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 14, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 14, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| May 1, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 1, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 1, 2018 | ALIE | ASSIGNED TO LIE | — |
| Apr 24, 2018 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Feb 9, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 3, 2018 | NWAP | NEW APPLICATION ENTERED | — |